OPINION
The potential of CD4+ regulatory T cells for the therapy of autoimmune diseases
1 Institute of Biology, Karelian Research Center of RAS, Petrozavodsk, Republic of Karelia
2 Perm State Pharmaceutical Academy, Perm, Russia
3 Kemerovo State Medical University, Kemerovo, Russia
Correspondence should be addressed: Alexey V. Churov
Pushkinskaya, 11, Petrozavodsk, 186910; ur.xednay@uoruhca
Funding: the study was carried out under state order for Karelian Research Centre (ID 0218-2019-0083; Modification of transcription programs of regulatory T cell differentiation in immunoinflammatory diseases and cancer). Its publication was sponsored by Prime Papers LLC.
Acknowledgements: the authors thank the Center for Precision Genome Editing and Genetic Technologies for Biomedicine (Moscow) for consultations.
Author contribution: Churov AV — article design, literature analysis, preparation of the manuscript draft and its final version; Syutkina AI — article design, the major contribution to literature analysis, preparation of the manuscript draft and its final version; Mamashov KY — article design, literature analysis, preparation of the manuscript draft and its final version; Oleinik EK — literature analysis, preparation of the manuscript draft and its final version.